BMS Bolsters China Compliance In Wake Of SEC Fine
This article was originally published in PharmAsia News
Following an investigation under the US Foreign Corrupt Practices Act violations, Bristol-Myers Squibb has been fined for improper business activities in China, which has been strengthening policies on drug price monitoring and to control kickbacks to doctors. The US firm says the matter has been resolved through a number of steps to improve practices and compliance.
You may also be interested in...
Continuing with a double-digit growth rate, China remained a leading driver for Sanofi’s global business in the fourth quarter. Going digital and building local partnerships emerged as key themes for Sanofi China to explore more opportunities, although it may face testing problems for its vaccine business in the country.
Oncologie acquires PS-targeting candidate bavituximab, which may help other cancer therapies in attacking tumors. BridgeBio's newest spinout will develop former Novartis cancer candidate infigratinib.
Strongbridge obtains rights from AEterna Zentaris to first drug approved for adult growth hormone deficiency. While the J.P. Morgan Healthcare Conference didn't have many major deal announcements, there was a flurry of announcements around discovery and development capabilities.